3-[(1-methylethyl)sulfanyl]propan-1-ol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-[(1-methylethyl)sulfanyl]propan-1-ol
• 英文别名: 1-Propanol, 3-[(1-methylethyl)thio]-；3-propan-2-ylsulfanylpropan-1-ol
• 化学式: C₆H₁₄OS
• 分子量: 134.243
• InChiKey: WSZGNYONAOZCRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-[(1-methylethyl)sulfanyl]propan-1-ol 在 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 3,3'-bis(7-tert-butyl-8-hydroxyquinolin-2-yl)-1,1'-binaphthyl-2,2'-diol 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以82%的产率得到
  参考文献：
  名称：

  Design of a New Bimetallic Catalyst for Asymmetric Epoxidation and Sulfoxidation

  摘要：

  A new chiral tethered 8-quinolinol-based ligand class is developed. The binuclear titanium complex of the ligand operates through a novel mechanism allowing for the regio- and stereoselective epoxidation of primary and tertiary homoallylic alcohols (up to 98% ee), as well as first examples of 2-allylic phenols (up to 92% ee). The new catalyst system also promotes the asymmetric oxidation of gamma-hydroxypropyl sulfides giving an important class of chiral sulfoxides that have been inaccessible to date (up to 95% ee).

  DOI：

  10.1021/jacs.5b11429
• 作为产物：
  描述：

  异丙硫醇 、 3-溴-1-丙醇 在 sodium 作用下， 以 乙醇 为溶剂， 反应 1.33h， 以97%的产率得到3-[(1-methylethyl)sulfanyl]propan-1-ol
  参考文献：
  名称：

  Design of a New Bimetallic Catalyst for Asymmetric Epoxidation and Sulfoxidation

  摘要：

  A new chiral tethered 8-quinolinol-based ligand class is developed. The binuclear titanium complex of the ligand operates through a novel mechanism allowing for the regio- and stereoselective epoxidation of primary and tertiary homoallylic alcohols (up to 98% ee), as well as first examples of 2-allylic phenols (up to 92% ee). The new catalyst system also promotes the asymmetric oxidation of gamma-hydroxypropyl sulfides giving an important class of chiral sulfoxides that have been inaccessible to date (up to 95% ee).

  DOI：

  10.1021/jacs.5b11429

文献信息

• PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：MIURA Tomoya

  公开号：US20130085132A1

  公开（公告）日：2013-04-04

  The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

  本发明提供了一种具有SGLT1抑制活性的下式[Ib]所示的吡唑化合物、或其药物可接受的盐、包含该化合物的药物组合物及其医药用途： 其中每个符号如说明书中所定义。
• Fused ring compound and use thereof
  申请人：Suzuki Hideo

  公开号：US20100190747A1

  公开（公告）日：2010-07-29

  The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

  本发明提供一种化合物，其化学式如下： 其中符号如规范中所述，或其盐，用于预防/治疗与前列腺素相关的疾病，如动脉粥样硬化、糖尿病、肥胖、动脉血栓形成、哮喘、发热、疼痛、癌症、风湿病、骨关节炎和特应性皮炎等，并具有优异的药理作用、理化性质等。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100105659A1

  公开（公告）日：2010-04-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病中非常有用，例如糖尿病。同时提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。
• Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：AICHER Thomas Daniel

  公开号：US20120277242A1

  公开（公告）日：2012-11-01

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  本发明提供了式(I)的化合物：其中R2、R3、R13、L和D2如规范中所定义，它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如在此处所讨论的。